Early prediction of late-pregnancy hypertriglyceridemia in women with gestational diabetes: development and internal validation of a clinical risk model - Report - MDSpire
Advertisement
Early prediction of late-pregnancy hypertriglyceridemia in women with gestational diabetes: development and internal validation of a clinical risk model
Clinical Report: Predicting Late-Pregnancy Hypertriglyceridemia in Gestational Diabetes
Overview
This study developed and validated a clinical risk prediction model for late-pregnancy hypertriglyceridemia (HTG) in women with gestational diabetes mellitus (GDM). The model incorporates five predictors.
Background
Gestational diabetes mellitus (GDM) is a prevalent metabolic complication during pregnancy, leading to significant maternal and neonatal risks. Hypertriglyceridemia (HTG) is a common manifestation in GDM that can result in adverse outcomes such as macrosomia and acute pancreatitis. Early identification of women at risk for HTG is essential.
Data Highlights
Metric
Value
Incidence of late-pregnancy HTG
32.7% (192/587)
AUC (held-out internal test set)
0.816 (95% CI: 0.754–0.878)
Optimism-corrected AUC
0.805
Calibration-in-the-large
-0.03
Calibration slope
0.94
Brier score
0.151
Scaled Brier score
0.301
Key Findings
The final model includes five predictors: pre-gravid BMI, fasting plasma glucose, 1-hour post-load glucose, first-trimester triglycerides, and first-trimester HDL-C.
The model showed good discrimination with an AUC of 0.816 in the internal test set.
Bootstrap internal validation indicated limited optimism with an optimism-corrected AUC of 0.805.
Decision curve analysis supported the model's clinical utility across relevant thresholds.
The model provided a modestly higher net benefit compared to a four-variable model excluding first-trimester triglycerides.
Clinical Implications
The developed prediction model can assist clinicians in identifying women with GDM at high risk for late-pregnancy HTG.
Conclusion
The study presents a validated prediction model for late-pregnancy HTG in women with GDM. Further external validation is necessary before clinical application.
